

Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis

NCT07298395

Status	RECRUITING
Phase	Phase 2
Sponsor	Enveda Therapeutics
Enrollment	64 participants

Key Eligibility Criteria

Inclusion (3)

- Have chronic atopic dermatitis that was diagnosed at least 12 months prior to the first study visit
- Have had either: (1) a poor response or intolerance to topical treatments for atopic dermatitis (such as corticosteroids) within the past 6 months, as determined by the study doctor, or (2) a poor response to treatments administered by mouth within the past 12 months.
- Use a bland moisturizer at least daily

Exclusion (5)

- Current or recurrent medical conditions that could affect the study drug or study assessments, including but not limited to: cardiovascular, neurological, kidney, liver, gastrointestinal, cancer, autoimmune disease, HIV, hepatitis B, hepatitis C, or psychiatric disorders.
- Any illness that could impact participant safety, clinically significant depression (as determined by the investigator), or active bacterial, fungal, or viral infections.
- Have an ongoing skin condition or large tattoos that would interfere with the clinical assessment, evaluation of atopic dermatitis, or treatment response.
- Have an ongoing clinically significant skin infection or receiving treatment for infection that may interfere with assessment of atopic dermatitis.
- Have clinically significant abnormal clinical laboratory assessments at the first or second study visit as determined by the Investigator.

Locations (17 total)

Cahaba & Skin Health Center, Birmingham, Alabama, United States
Burke Pharmaceutical Research, Hot Springs, Arkansas, United States
Center for Dermatology Clinical Research, Fremont, California, United States
... and 14 more locations